Using a Drosophila model of MECP2 gain-of-function, we identified memory associated KIBRA as a target of MECP2 in regulating dendritic growth. We found that expression of human MECP2 increased kibra expression in Drosophila, and targeted RNAi knockdown of kibra in identified neurons fully rescued dendritic defects as induced by MECP2 gain-of-function. Validation in mouse confirmed that Kibra is similarly regulated by Mecp2 in a mammalian system. We found that Mecp2 gain-of-function in cultured mouse cortical neurons caused dendritic impairments and increased Kibra levels. Accordingly, Mecp2 loss-of-function in vivo led to decreased Kibra levels in hippocampus, cortex, and cerebellum. Together, our results functionally link two neuronal genes of high interest in human health and disease and highlight the translational utility of the Drosophila model for understanding MECP2 function.
Introduction
Methyl-CpG binding protein 2 (MECP2) is a widely abundant, multifunctional regulator of gene expression with highest levels of expression in mature neurons. In humans, both loss-and gain-of-function mutations of MECP2 cause mental retardation and motor dysfunction classified as either Rett Syndrome (RTT, loss-of-function) (Amir et al., 1999) or MECP2 duplication syndrome (MDS, gain-of-function) (Ramocki et al., 2010) . In patients and in mouse models both MECP2 loss-and gain-of function can cause changes in dendritic morphology (Armstrong, 2005; Cheng et al., 2014; Wang et al., 2013; Zhou et al., 2006) . While there is no MECP2 ortholog in Drosophila, we recently found that expression of human MECP2 (hMECP2) severely reduces the dendritic complexity of identified Drosophila motoneurons while maintaining normal membrane currents (Vonhoff et al., 2012) .
Short generation times, facile tools for genetic manipulation (Venken and Bellen, 2005) , and a high degree of conservation in fundamental cell biological pathways involved in neuronal development (Degerny et al., 2009; Louvi and Artavanis-Tsakonas, 2006; Rubin et al., 2000) make Drosophila a powerful model to study the cellular and molecular mechanisms by which MECP2 acts to impact dendritic structure. Because the Drosophila genome contains low 5-methylctosine (5′mC) levels (Capuano et al., 2014) , it is not expected that this system can be used to elucidate mechanisms associated with the classical 5′mCpG dependent transcription repression function of MECP2 (Nan et al., 1997) . However, MECP2 has also been shown to activate transcription (Chahrour et al., 2008) and many additional cellular functions of MECP2 have been identified which do not require binding to methylated DNA (Cheng et al., 2014; Georgel et al., 2003; Hansen et al., 2010; Skene et al., 2010; Young et al., 2006) . Further, other proteins with methyl binding domains (MBD) exist in Drosophila, and many MECP2 interactors, including other parts of the chromatin modifying machinery, have well conserved orthologs (Hendrich and Tweedie, 2003) . When expressed in Drosophila, hMECP2 associates with chromatin, can be modified by orthologs of known interacting proteins, and, like in mammals, is phosphorylated at serine 423 (Cukier et al., 2008) , and causes specific defects in dendritic morphology (Vonhoff et al., 2012) . Furthermore, as observed in humans and mouse models (Collins et al., 2004; Ramocki et al., 2010; Van Esch, 2011) , hMECP2 expression in Drosophila causes impairments in motor behavior (Cukier et al., 2008; Vonhoff et al., 2012) .
Here, we use RNA-Seq with our Drosophila gain-of-function model to identify KIBRA as a novel gene activated by MECP2 and required for dendritic impairments. Validation in mouse confirms that Mecp2 gainof-function similarly causes dendritic defects in primary cortical neuron culture coupled with increased Kibra levels. Similarly, we find that loss of Mecp2 decreases Kibra levels in mouse hippocampus, cortex, and 
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